Kimberly Ha notes that many big pharma companies are partnering with academic institutions and that oncology, followed by neurology is one of the hottest areas in acquisitions
Browsing: Uncategorized
OneMedForum SF 2012 is around the corner and we are gearing up to present some of the most promising companies and technologies, as well as innovative approaches to funding the growth economy. In this issue: EpiCept Corporation [EPCT.PK]will present its Cancer product, Ceplene, approved in the European Union along with three other products, which stand as major clinical trial candidates: Amiket, Crobulin, and Azixa. S.E.A. Medical Systems, developing systems for intravenous drug delivery, will be presenting their technology at OneMedForum SF 2012. GlySure Limited has successfully demonstrated the ability to continuously monitor glucose levels for ICU patients’ length of stay…
Ceplene is administered for maintenance of first remission in patients with AML, the most common type of Leukemia in adults.
Mark Tauscher, President and CEO of PLC Medical Systems Inc., discusses the company’s product RenalGuard, an important tool for ridding the body of toxins.
DMP estimates that the market for treating GBM patients post front-line therapy exceeds US$200 million annually in North America.
Peter Winter, consultant to the biotechnology industry brings us financings and business developments in the global diagnostics business in his column “This Week In Diagnostics“. Peter has over 30 years experience as a scientist, science journalist, and publisher.
Inovio Pharmaceuticals (AMEX:INO) won the Edward Jenner Poster Award First Prize for its research to develop a therapeutic, synthetic vaccine for cancer.
OneMedRadio interviewed Tom Moore, CEO and Chairman of the Board of Directors of Advaxis [OTC:ADXS]. He discusses the company’s novel immunotherapy technology.